secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001437749-25-026971
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q2 2025 net loss $6.1M ($0.12/share); cash $10.4M; brilaroxazine OLE data positive
--------------------------------------------------------------------------------

- Net loss $6.1M vs $7.9M YoY; cash $10.4M as of June 30, 2025, down from $13.5M at Dec 2024.
- Completed Phase 3 RECOVER OLE 1-year trial: brilaroxazine sustained PANSS total score -18.1 over 1 year.
- FDA meeting planned Q4 2025 for path to approval; potential NDA submission targeted Q2 2026.
- Completed $10.0M public equity offering in Q2 2025.
- Plans to assess registrational Phase 3 RECOVER-2 pending FDA feedback; IND for psoriasis formulation expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/0001437749-25-026971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/rvph20250805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-026971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer